ADRIAN POWELL THOMAS, MD, FRACP, MRACMA

INDUSTRY EXPERIENCE

Janssen, the Pharmaceutical Companies of Johnson & Johnson ***Raritan, NJ, USA***

Head, Global Public Health 2013-Current
Vice President and Global Head, Global Commercial Strategy Organization 2011-Current
President and Company Officer, Janssen Global Services LLC 2011-Current

- Global responsibility for the cluster of commercial and scientific functions supporting Janssen, including Global Medical Affairs; Global Health Economics; Global Pharmaceutical Pricing; Global Strategic Analytics; Strategic Marketing Excellence; Global Access Policy; and Patient Reported Outcomes.

World Wide Vice President, Market Access 2009-2011

- Global responsibility for Health Economics, Pharmaceutical Pricing, and Patient Reported Outcomes.

Global Head, Benefit Risk Management & Chief Safety Officer, Pharmaceuticals 2007-2009

- Global responsibility for the benefit-risk management of J&J pharmaceutical products.

Vice President, Safety Sciences, Informatics & Operations 2005-2007

- Responsibility for epidemiology, surveillance, safety systems and operational processing for J&J pharmaceutical products, both R&D and marketed.

Head of Global Clinical Safety & Epidemiology, J&J Pharmaceutical R&D 2002-2005

- Global responsibility for post-marketing surveillance and epidemiology for pharmaceutical products.

Asia-Pacific Regional Head of Drug Safety & Surveillance, Janssen Research Foundation 2001-2002

- Responsibility for Asia-Pacific Region & global safety for select biologic therapies.

Schering-Plough Corporation ***Kenilworth, NJ, USA***
Australasian Medical Affairs Director, Schering-Plough 1999-2001

- Responsibility for Medical Affairs functions in Australia and New Zealand.

Eli Lilly & Company ***West Ryde, New South Wales, Australia***

Associate Medical Director, Australia & New Zealand 1998-1999
Associate Medical Director, Clinical Research 1997-1998
Clinical Research Physician, Eli Lilly 1995-1997

- Various roles in drug development and medical affairs.

ACADEMIC TEACHING & ADMINISTRATIVE EXPERIENCE

Temple University ***Philadelphia, PA, USA***
Quality Assurance/Regulatory Affairs Program 2006-Current
Adjunct Professor

National University of Singapore ***Singapore***
Singapore Academy of GxP Excellence (SAGE) 2008
Steering Committee Member

Monash Medical Center ***Melbourne, Victoria, Australia***
Senior Medical Staff: Hypertension & Vascular Medicine 1995-1997

- Investigation, diagnosis and management of complex hypertension patients in the outpatient and inpatient setting.
- Research Fellow, antioxidant research and epidemiology research, Public Health Research and Development Fellow (PH&RDC of NH&MRC).
- Assessor, Quality Indicators in Hospital Care (QUALITY) Study.
- Research Fellow, Department Epidemiology & Preventive Medicine.

Monash University ***Melbourne, Victoria, Australia***
Alfred Medical School 1993-1997

- Associate Sub-Dean Faculty of Medicine
- Lecturer and coordinator, fifth-year medicine teaching program
- Lecturer and tutor in Epidemiology, Prevention Medicine and Bio-Statistics

National Health & Medical Research Council Research Scholar ***Melbourne, Victoria, Australia***
Department of Epidemiology & Preventive Medicine 1993-1997

Melbourne University Private ***Melbourne, Victoria, Australia***
Sub-Dean, Austin Hospital Clinical School 1992-1994

- Designed, implemented and administered clinical training program for 300+ third- through sixth-year medical students based at a large specialist tertiary referral hospital.
- Oversaw clinical examinations for medical program and specialist training programs in internal medicine conducted at the Austin hospital.

Royal Australasian College of Physicians ***Melbourne, Victoria, Australia***
Internal Medicine Training Program 1991-1994

- Vascular medicine & clinical pharmacology

University of Melbourne ***Melbourne, Victoria, Australia***

- Medical faculty, Clinical Supervisor, Internal Medicine 1989

EDUCATION & PROFESSIONAL CREDENTIALS

University of Melbourne ***Melbourne, Victoria, Australia***
Doctor of Medicine (MD) degree 1989
Bachelor of Medicine (MBBS) degree
Graduate and Undergraduate Medical Training
University of Melbourne, Medical Faculty
Royal Melbourne Hospital Clinical School

Fellow, Royal Australasian College of Physicians ***Australia***
Member, Royal Australasian College of Medical Administrators ***Australia***

MILITARY SERVICE

Royal Australian Armoured Corps 1980-1983
4th /19th Prince of Wales Light Horse Regiment B Squadron
(Trooper/Gunner/Driver/Signaller M113 A1 Armoured Personnel Carrier)
Royal Australian Army Reserve, Officer Training School

MISCELLANEOUS

Lethbridge Wines, a commercial vineyard 1996-Current
Founder/Partner

Aspen Institute First Mover Fellow 2013

SELECT PUBLICATIONS & PRESENTATIONS *(abbreviated list)*

- Witness, U.S. House of Representatives hearing on "Meeting the Challenge of Drug-Resistant Diseases in Developing Countries." Written testimony delivered on behalf of Johnson & Johnson before the House Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations: Washington, DC, April 2013.
- Panelist, U.S.-China Food and Drug Law Conference, "Innovation and Access: Key Success Factors in China," hosted by the Food & Drug Law Institute, Beijing, June 2011.
- Presenter and panelist, University of Miami Global Business Forum, "Incentives for Innovation: Who's the customer?" January 2011.
- Co-author, "Comparative Effectiveness, Personalized Medicine and Innovation: The Path Forward." *PharmacoEconomics*, October 2010.
- Contributor, *Canadian Roundtable on Clinical Considerations for Subsequent Entry Biologics*, "The Global Experience with Subsequent Entry Biologics," May 2009.
- Co-editor, *Global Pharmacovigilance Laws and Regulations: The Essential Reference*, Food and Drug Law Institute, April 2009.
- Spokesperson for Johnson & Johnson on the topic of the Healthcare Notification Network (HCNN) partnership, October 2008.
- Presenter, Brandeis University Health Industry Forum, "Enhancing Post-Marketing Surveillance," April 2007.
- Co-author, "Pharmacovigilance," Chapter 9 of *The Learning Healthcare System: Workshop Summary*, a publication of the Institute of Medicine, Washington, DC, 2007.
- Invited witness, U.S. Senate hearing on "Building a 21st Century FDA: Proposals to Improve Drug Safety and Innovation." Testimony delivered on behalf of Johnson & Johnson before the Senate Committee on Health, Education, Labor, and Pensions: Washington, DC, November 2006.
- Presenter, "Epidemiology and surveillance in a billion dollar whodunit," Seminar Series, Monash University Department of Epidemiology & Preventive Medicine, Melbourne, Australia, August 2004.

Committee on Energy and Commerce
U.S. House of Representatives

Witness Disclosure Requirement - "Truth in Testimony"
Required by House Rule XI, Clause 2(g)

1. Your Name: Adrian Thomas, MD, FRACP		
2. Are you testifying on behalf of the Federal, or a State or local government entity?	**Yes**	**No** X
3. Are you testifying on behalf of an entity that is not a government entity?	**Yes** X	**No**
4. Other than yourself, please list which entity or entities you are representing: **Janssen Research and Development, L.L.C**		
5. Please list any Federal grants or contracts (including subgrants or subcontracts) that <u>you or the entity you represent have received</u> on or after October 1, 2011: **See attached**		
6. If your answer to the question in item 3 in this form is "yes," please describe your position or representational capacity with the entity or entities you are representing: **I am Vice President, Global Market Access & Commercial Strategy Operations and Head, Global Public Health**		
7. If your answer to the question in item 3 is "yes," do any of the entities disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony?	**Yes** X	**No**
8. If the answer to the question in item 3 is "yes," please list any Federal grants or contracts (including subgrants or subcontracts) that were received by the entities listed under the question in item 4 on or after October 1, 2011, that exceed 10 percent of the revenue of the entities in the year received, including the source and amount of each grant or contract to be listed: **None**		
9. Please attach your curriculum vitae to your completed disclosure form. **See attched**		

Signature: [redacted] **Date:** 9-17-2014

Contract Number	Disease Area	Period of Performance	Crucell as subcontractor	Primary Contract / Grant holder	Amount Awarded (USD)	Awarding Party
IPCAVD - 1- A1066305	HIV Vaccine Research*	2005-2011	Yes	Harvard University	8.4MM**	NIAID
IPCAVD -2- multivalent A1078526	HIV Vaccine Research*	2008-2013	Yes	Harvard University	27.7MM	NIAID
IPCAVD -3- A1096040	HIV Vaccine Research*	2012-2017	Yes	Harvard University	7.5MM	NIAID
HHSN272200800056C	Multivalent Filovirus Vaccine Development	2008-2015	No	Crucell	13.4MM	NIAID
HHSN272200800056C	Multivalent Filovirus Vaccine Development	2010-2015	No	Crucell	17.4MM	NIAID
HHSN272200800056C	Multivalent Filovirus Vaccine Development	2010-2015	No	Crucell	3.5MM	NIAID
N01-A1-05421	Malaria Vaccine Research	2008-2011	Yes	SAIC	2.9MM	NIAID
Under LOI (MVI-Crucell)	Malaria Vaccine Research	2010-2012	Yes	MVI	2.0MM	USAID
HHSN272200900060C	Infectious Disease – Respiratory - Flu A	2009-2014	No	Crucell	47.0MM	NIAID

*not a "neglected" disease, but included due to its profound importance in many developing countries

**Much, probably over half, spent prior to the period in question